Human monoclonal antibodies to lung-cancer antigens. by Sikora, K. & Wright, R.
Br. J. Cancer (1981) 43, 696
HUMAN MONOCLONAL ANTIBODIES TO
LUNG-CANCER ANTIGENS
K. SIKORA AND R. WRIGHT
From the M.R.C. Clinical Oncology and Radiotherapeutics Unit, The Medical School,
Hills Road, Cambridge
Recei\edI 6 October 1980 Accepted 19 JanIuary 1981
Summary.-Lymphocytes obtained from hilar and bronchial lymph nodes from 23
patients undergoing radical surgery for carcinoma of the bronchus were fused with
established rat or mouse myeloma lines. 62% of the resultant hybrids were found to
be secreting human Igdetected by a sensitive staphylococcal Protein A-coupled SRBC
assay. Immunoglobulins synthesized by such hybrids were internally labelled with
3H-lysine and their antibody activity against a variety of membrane preparations
determined. Nine monoclonal antibodies were found which bound to molecules on
lung-cancer membranes and not on normal lung membranes from the same patient.
A MAJOR PROBLEM in clinical oncology
is the measurement of tumour load in an
individual patient. This hampers the
evaluation ofdifferent treatment methods,
especially in the case of the common solid
tumours. There is now considerable evi-
dence that human tumour cells possess
membrane components recognized by the
host's immune system. Evidence for the
presence of these tumour-specific antigens
comes from serological studies (Schultz
et al., 1975), in vitro cell-mediated systems
(Baldwin, 1975) and delayed cutaneous
hypersensitivity tested with tumour-cell
extracts (Hollinshead et al., 1974). Such
antigens may well be shed into the blood
stream, and ifa sensitive andreliable assay
for them could be developed they might
well provide a new series of tumour mar-
kers. The use of conventional serology to
detect such components has been exten-
sivelyexplored(Gaffaretal., 1979). Tumour
fragments have been used to immunize a
variety of laboratory animals. Unfor-
tunately the predominant response in such
xenogeneic immunizations is against sur-
face molecules common to normal and
malignant tissue, such as blood-group
glycoproteins and histocompatibility anti-
gens. After absorption of such antisera
with normal tissue little specific anti-
tumour activity remains.
The production of homogeneous mono-
clonal antibodies has revolutionized our
ability to unravel complex antigenic struc-
tures such as cell membranes. Several
groups have investigated the production
of monoclonal antibodies to a variety of
human tumours, including leukaemia
(Levy et al., 1979), lymphoma (Reinherz
et al., 1979), colorectal carcinoma (Herlyn
et al., 1979), melanoma (Yeh-et al., 1979)
and lung cancer (Huberman et al., 1979).
Such antibodies were derived by fusing
spleen cells from mice immunized with
human tumour material with an estab-
lished myeloma line (Kohler & Milstein,
1975). Although such xenogeneic anti-
bodies are of considerable interest, it is the
antigenic determinants seen as foreign by
the patient's immune system that we most
wish to identify. Such determinants are
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more likely to provide the necessary
specificity for diagnostic, monitoring and
therapeutic exploitation.
In this paper we describe the production
of human monoclonal antibodies against
lung-cancer antigens. Carcinoma of the
bronchus was chosen for study for several
reasons. Firstly, there is good evidence for
an immune response to the tumour both
serologically and tlhrough cell-mediated
mechanisms (Takasugi et al., 1974).
Secondly, reasonable quantities ofregional
lymph node, tumour and normal lung are
available at surgery forprocessing. Finally,
most bronchial carcinomas are presum-
ably carcinogen-induced, and thus may be
analogous to the highly immunogenic
carcinogen induced tumours of experi-
mental animals (Sikora et al., 1979).
MATERIALS AND METHODS
Lymphocytes for fusion.-Material was col-
lected from patients undergoing lobectomy or
pneumonectomy for operable carcinoma of
the bronchus. At thoracotomy, tumour,
normal lung and hilar or bronchial lymph
nodes were removed and placed in sterile
saline. A piece of each was removed for pro-
cessing and the remainder examined histo-
logically. The lymph node was teased apart
in sterile culture medium consisting of
Dulbecco's modification of Eagle's medium,
20% foetal calf serum, penicillin (100 iu/ml)
and streptomycin (100 jug/ml). The resulting
cell suspension was layered on to Ficoll
Hypaque and centrifuged at room tempera-
ture for 30 min at 400 g. Cells collecting at the
interface were harvested and washed x 3 in
medium.
Fusion and selection.-The cells were
counted and mixed with an equal number of
myeloma cells; either P3 NSI/lAg4.1 (a non-
immunoglobulin-producing mouse myeloma)
or Y3 Agl.2.3 (a rat myeloma). The lympho-
cyte-myeloma mixture was washed x 3 in
serum-free medium and resuspended in 38%
polyethylene glycol (Baker 1540). The cells
were centrifuged at 1000 rev/min for 5 min
and the polyethylene glycol removed. After
several washes the cells were suspended in
selective medium containing hypoxanthine,
aminopterin and thymidine (Kohler & Mil-
stein, 1975) and plated into 24-well Linbro
culture plates. The selective medium pre-
vented the growth of unfused myeloma cells.
After 2-4 weeks, hybrid colonies were seen in
some of the wells. The supernatants were
removed and tested for human Ig content,
using a Protein A-coupled SRBC lysis assay.
Staphylococcal Protein A (Pharmacia) was
coupled to fresh sheep erythrocytes by CrCl3
(Poston, 1974). 200 pl of packed Protein A-
coupled red cells was added to 2 ml of 0.6%
agarose together with 5 ,ul of rabbit anti-
human Ig (a gift from Dr D. Voak, East
Anglian Regional Blood Transfusion Service).
The agarose mixture was allowed to set on a
Petri dish and lil amounts of supernatant
added. After 1 h the plate was developed by
the addition of complement (guinea-pig
serum diluted 1:10). After 3h incubation at
37°C in a moist incubator, areas of lysis
occurred where human Ig was present in the
supernatant and formed a complement-
activating complex with the rabbit anti-
human Ig and the Protein A bound to the red
cells. This assay was shown to detect human
Ig at concentrations >0 1 Hg/ml. Hybrids
secreting Ig were cloned by serial doubling
dilution and wells containing single hybrid
colonies pulsed with 3H-lysine (3H-LYS).
Cells were incubated in 0-5 ml of cold lysine-
free medium containing 50 ,uCi of 3H-LYS
(Radiochemical Centre, Amersham) for 16 h.
Bintding assay.-Labelled immunoglobulins
were collected, dialysed overnight against
phosphate-buffered saline and tested for anti-
body activity by binding assays to a variety
of human tumour and normal tissue mem-
branes prepared by the method of Lennox &
Takei (submitted for publication). These in-
cluded membranes from the patient's own
tumour and normal lung. Membranes were
absorbed on to a vinyl microtitre plate by
incubation at 4°C overnight. After washing
in the assay medium (Earle's buffered salt
solution containing 1% bovine serum albu-
min) 20 ,ul of labelled supernatant was added
to each well in triplicate. After 2 h at room
temperature the plate was washed and 20 dul
of2N sodium hydroxide added to each well to
solubilize bound proteins. After neutralizing
with 20 ,ul of HCI the contents of each well
were added to 10 ml of Aquasol and counted
on a scintillation counter. The presence of
intact cell-surface antigens on the vinyl plate
was verified by the binding of a monoclonal
anti-common HLA antibody W6/32 HL
kindly provided by Dr G. Galfre (Barnstaple
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et al., 1978). The overall strategy is outlined
in Fig. 1.
RESULTS
Hybrid production
Material suitable for fusion was collected
from 23 patients with carcinoma of the
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bronchus. Details of the patients and the
results of fusions are included in Table I.
Successful hybrids were obtained from 12
patients. Although possible early growth
ofhybrid colonies were seen in some ofthe
remaining patients, these were not further
analysed. There was no apparent correla-
tion between successful hybridization and
the age, sex or blood group of the patient.
The fusion frequency was not dependent
on the myeloma used. 62% of the hybrids
were found to secrete human Ig to a
concentration > 01 mg/ml 4 weeks after
fusion. Immunoglobulin production ceased
by the 10th week after fusion in all
hybrids, although no other changes in the
cells were seen at this time.
Immunoglobulin binding
Hybrids which were secreting high
concentrations of human Ig were pulse
labelled with 3H-LYS 6-8 weeks after
fusion. Binding of the labelled Igs to
membrane preparations from the patient's
own tumour and normal lung was meas-
ured (Fig. 2). Nine hybrids were found,
all derivedfrom Patient 17, which secreted
human immunoglobulin binding to lung-
tumour membranes. The specificity of
TABLE I. Details ofpatients and hybrids
Number
Bloo(d Tumotur l Fusioin of
Age Sex group histology myeloma hybrids
53 MA A- Adeno Y3 6
56 Al A+ Squamouis Y3 :36
55 F B+ Squamous NSI 17
60 AI A + Squamouis Y3
68 AM B + Squamous Y3 0
62 Al A + Squamous Y3 0
63 AI: 0 + Squamous NSI 12
57 AM, A + Squamouis NS l 32
68 F A + Squamous NSI 72
55 F 0- Large-cell Y3 1 9
66 AM 0C- Squamouis NS 7
72 M A - Squamouis Y3
54 1\I A + Adeno NSI
60 1\ A- A(leno Y3
60 M A Squamous NS I
65 Al B + Squamous Y3
68 MI A + Squamous Y3 36
53 + Squamouis Y3 I1
60 M1 A- Squamouis NS] 144
62 F 0 + Squamouis NSI
64 Mr () + Squamotus Y3
66 II A- Squiamouis Y3
56 A1 () + Squiamouis NSI 1:3
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FIGJC;. 2. Binding of 3H-lysine to (a) I'atient
17 ltung-tumour membranes andl (b) Patient
17 niormal lung membranes. Assay per-
forme(d in triplicate.
binding to avariety of membrane prepara-
tions was examined (Table II). None of
the Igs bound to the patient's normal lung
or to normal tissue membranes from other
TABLE II. Binding specificity of antibodies
ct/min: -<
patients. There was, however, binding to
lung-tumour membranes from other pa-
tients. Although a total of 31 Ig-secreting
hybrids from 7 patients were pulse-
labelled with 3H-LYS, binding to auto-
logous tumour-membrane preparation was
found only in Patient 17.
DISCUSSION
Monoclonal antibodies provide an excel-
lent tool with which to examine tumour
cell surfaces. By fusing lymphocytes from
cancer patients we hoped to immortalize
human Igs against individual tumour-
specific antigensrecognizedbythepatient's
immune system. There is evidence from
experimental tumour models that lympho-
cytes from tumour-bearing animals can be
stimulated to produce anti-tumour anti-
bodies, which can be produced in large
quantities by cell fusion (Simrell & Klein,
1979). The fusion frequency for human-
mouse and human-rat hybridization was
much lower than that found using the
same myeloma cells for mouse-mouse
or rat-rat hybridization. This probably
reflects species preferences for hybrid
growth. 62o of the hybrids secreted
human Ig in significant amounts. The
ability to secrete Ig was lost by the 10th
week after fusion, almost certainly owing
to the loss of the human chromosomes
involved in Ig synthesis.
Internal labelling of Ig was found to be
necessary for detection ofbinding activity.
Assays with unlabelled products were un-
reliable as variable quantities of human
Ig were present in tumour and normal
internally labelled with 3H-lysine. + > 200
- 200 ct/min
Hybrid numbers
Mllembranes
P't. 17 Lung tumour
Pt. 17 Normal lung
Normal lymphocytes
Normal re(l bloodl cells
Normal colon
Pt. 19 Lung tumour
Pt. 20 Lung tumoui
Pt. 22 Luing tumour
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membrane preparations, giving a high
background in double-layer radioimmuno-
assays using anti-human antibody as
developing reagent. Only one patient's
hybrids produced antitumour antibodies.
This patient was a 68-year-old man who
had smoked 30 cigarettes daily for over 40
years. He was found to have a well differ-
entiated squamous carcinomainvading 4/8
hilar lymph nodes. It is possible that this
patient had a particularly immunogenic
tumour. The molecular nature ofthe deter-
minants recognized by the antibodies
remains to be determined. It is clear that
they are present on tumours from several
patients. By developing further sets of
human monoclonal antibodies we hope to
learn more about the components they
recognize. These might well provide useful
tumour markers. In addition the produc-
tion of stable Ig-producing lines would
enable larger quantities of antibody to be
collected for therapeutic use. A human
tumour line suitable forfusion and produc-
ing stable hybrids has recently been
discovered (Olsson & Kaplan, 1980).
We thank Drs Giovanni Galfre and Ed Lennox
and Mr Bruce Wright for their helpful advice and
provision of myeloma lines. We thank Mr Terence
English, Mr Ben Milstein and Dr Peter Stovin for
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